Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials

The cardiovascular safety of liraglutide, a glucagon‐like peptide‐1 receptor agonist approved for weight management at a dose of 3.0 mg, was evaluated post hoc using data from 5908 participants in 5 randomized, double‐blind, placebo‐controlled clinical trials. Participants were randomized to liraglu...

Descripción completa

Detalles Bibliográficos
Autores principales: Davies, M. J., Aronne, L. J., Caterson, I. D., Thomsen, A. B., Jacobsen, P. B., Marso, S. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2017
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836948/
https://www.ncbi.nlm.nih.gov/pubmed/28950422
http://dx.doi.org/10.1111/dom.13125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836948/
https://www.ncbi.nlm.nih.gov/pubmed/28950422
http://dx.doi.org/10.1111/dom.13125

Ejemplares similares